Reference drugs for triple combination test drug in Russia [Design Issues]

posted by mittyri – Russia, 2019-11-15 23:29 (520 d 17:35 ago) – Posting: # 20811
Views: 3,512

Hi PharmCat!

» Anyway can be some exceptions when this rule not work. May be it can be orphan drugs or some individual cases or regulatory abuse.
"The exception that proves the rule"
Just what I have found in GRLS and that drugs were approved within a BE study against 2 Reference drugs
Amlodipine + Indapamide + Perindopril
Losartan + Amlodipine + Rosuvastatin
Indapamide + Rosuvastatin + Perindopril
(could be more, lazy to search)

I would not name it 'orphan' or 'individual' :-)
Generic companies did develop almost all attractive double combinations for cardiovasulcar diseases and were trying to expand to triple combinations.

Kind regards,
Mittyri

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 9 (0 registered, 9 guests [including 2 identified bots]).
Forum time: Monday 18:05 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5